CBFA2T3-GLIS2 model of pediatric acute megakaryoblastic leukemia identifies FOLR1 as a CAR T cell target (vol 132, e157101, 2022)JOURNAL OF CLINICAL INVESTIGATIONIF13.62024-08-150OAAI
Preclinical studies targeting CD74 with STRO-001 antibody-drug conjugate in acute leukemiaBLOOD ADVANCESIF7.12023-04-267OAAI
Therapeutic targeting of PRAME with mTCRCAR T cells in acute myeloid leukemiaBLOOD ADVANCESIF7.12023-03-3117OAAI
Targeting FOLR1 in high-risk CBF2AT3-GLIS2 pediatric AML with STRO-002 FOLR1-antibody-drug conjugateBLOOD ADVANCESIF7.12022-11-225OAAI
CBFA2T3-GLIS2 model of pediatric acute megakaryoblastic leukemia identifies FOLR1 as a CAR T cell targetJOURNAL OF CLINICAL INVESTIGATIONIF13.62022-11-1522OAAI
Therapeutic targeting of CBFA2T3-GLIS2 infant AML with ELU001-folate receptor alpha-directed C'Dot-drug-conjugateCANCER RESEARCHIF16.62022-06-151PRE
Therapeutic Targeting of Mesothelin with Chimeric Antigen Receptor T Cells in Acute Myeloid LeukemiaCLINICAL CANCER RESEARCHIF10.22021-08-114OAAI
Mesothelin is a novel cell surface disease marker and potential therapeutic target in acute myeloid leukemiaBLOOD ADVANCESIF7.12021-05-0320OA
Notch blockade overcomes endothelial cell-mediated resistance of FLT3/ITD-positive AML progenitors to AC220 treatmentLEUKEMIAIF13.42020-06-084PREAI
Comprehensive Transcriptome Profiling of Cryptic CBFA2T3-GLIS2 Fusion-Positive AML Defines Novel Therapeutic Options: A COG and TARGET Pediatric AML StudyCLINICAL CANCER RESEARCHIF10.22020-02-0345OAAI
Activation-induced deaminase (AID) localizes to the nucleus in brief pulsesPLOS GENETICSIF3.72019-02-276OAAI
Cell Cycle Regulates Nuclear Stability of AID and Determines the Cellular Response to AIDPLOS GENETICSIF3.72015-09-1033OAAI